PRO/AH/EDR> Zika virus (02): Americas, Africa, research, observations

Zika virus — Costa Rica
Background
Zika virus (ZIKV) may cause severe congenital disease after maternal-fetal transmission. No vaccine is currently available.
Objective
To assess the safety and immunogenicity of Ad26.ZIKV.001, a prophylactic ZIKV vaccine candidate.
Design
Phase 1 randomized, double-blind, placebo-controlled clinical study. (ClinicalTrials.gov: NCT03356561)
Setting
United States.
Participants
100 healthy adult volunteers.
Intervention
Ad26.ZIKV.001, an adenovirus serotype 26